A Phase 1, Open Label, Dose Escalation, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR104 in Patients with Select Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs XL 114 (Primary)
- Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms VIJAY-1
- Sponsors Aurigene Oncology
- 14 Jan 2025 New trial record